Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01159990 · ClinicalTrials.gov registry record · Phase 1
Antigenic Competition in HIV Preventive Vaccines
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT01159990 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 100 participants.
The verdict
NCT01159990, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
HIV vaccines are designed to create an immune response to certain components of the HIV virus called peptides. Previous research indicates that one peptide, called Gag, may be particularly important for stimulating an immune response to HIV. Many vaccines being studied combine multiple peptides, but including other peptides may weaken the body's response to Gag. This study will test whether a vaccine that targets Gag and another peptide called Env is better than a vaccine without Env at causing an immune response to Gag.
Interventions
- BIOLOGICAL rAd5 Gag-Pol Env A/B/C
- BIOLOGICAL rAd5 Gag-Pol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2011-01 |
| Est. Completion | 2017-04-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01159990
The ClinicalTrials.gov registry entry for NCT01159990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which rAd5 Gag-Pol Env A/B/C is the first listed.
NCT01159990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01159990 about?
NCT01159990 is a clinical study titled "Antigenic Competition in HIV Preventive Vaccines". HIV vaccines are designed to create an immune response to certain components of the HIV virus called peptides. Previous research indicates that one peptide, called Gag, may be particularly important for stimulating an immune response to HIV. Many vaccines being studied combine multiple peptides, but...
What is the current status of trial NCT01159990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2011-01. Estimated completion is 2017-04-06.
What interventions are being tested in trial NCT01159990?
The interventions under investigation include: rAd5 Gag-Pol Env A/B/C (BIOLOGICAL), rAd5 Gag-Pol (BIOLOGICAL).
Who is sponsoring clinical trial NCT01159990?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.